Overview

Tacrolimus and Mycophenolate Mofetil in Preventing Acute Graft-Versus-Host Disease in Patients With Advanced Hematologic Cancer Who Are Undergoing Donor Stem Cell Transplantation

Status:
Completed

Trial end date:
1969-12-31

Target enrollment:

Participant gender:

Summary

RATIONALE: Tacrolimus and mycophenolate mofetil may be an effective treatment for graft-versus-host disease caused by donor stem cell transplantation. PURPOSE: This phase II trial is studying how well giving tacrolimus together with mycophenolate mofetil works in preventing acute graft-versus-host disease in patients who are undergoing donor stem cell transplantation for advanced hematologic cancer.

Phase:

Phase 2

Details

Lead Sponsor:

Fred Hutchinson Cancer Research Center

Collaborator:

National Cancer Institute (NCI)

Treatments:

Mycophenolate mofetil
Mycophenolic Acid
Tacrolimus